JACOBIO-B

Jacobio Pharmaceuticals opened at HKD 5.17 and surged to an intraday high of HKD 5.825 (up 18.9% from the previous close), but gradually retreated in the afternoon session to close at HKD 5.440, still up 11.0%. The sharp intraday swing was driven by the company's forecast of a net profit of at least RMB 600 million in H1, coupled with multiple share buybacks at HKD 4.64-5.08 and clinical progress (JAB-8263 for rheumatoid arthritis Phase IIa, JAB-23E73 for pancreatic cancer Phase Ib/III). However, the closing price was well below the morning peak, indicating profit-taking, while the stock trades at a PB of 4.99x and a negative PE.

Jacobio Pharmaceuticals opened higher and then pulled back during the morning session, reaching an intraday high of HKD 5.11 before retreating to HKD 5.05, up 4.45% from the previous close of HKD 4.835, though turnover remained thin at just 95,100 shares. The company has recently disclosed multiple share repurchases and cancellations, while advancing its pipeline with first patient dosing in the Phase IIa trial of JAB-8263 for rheumatoid arthritis and the Phase Ib/III trial of pan-KRAS inhibitor JAB-23E73 in KRAS-mutant pancreatic cancer. However, Q4 2025 operating revenue plummeted 94.72% YoY to HKD 4.37 million, while net loss widened to HKD 48.37 million, with EPS deteriorating 779.73% YoY. The stock remains 57.2% below its 52-week high of HKD 11.8 and has underperformed YTD with a 21.34% decline, trading below both the MA20 (HKD 4.898) and MA60 (HKD 4.822), indicating persistent weakness.

Jacobio Pharmaceuticals closed at HKD 4.675 in the afternoon session, up 5.06% from the previous close of HKD 4.45, with an intraday range of 7.1% and a low of HKD 4.36 near the 52-week bottom of HKD 3.98. The rally was driven by the initiation of a Phase Ib/III trial for the pan-KRAS inhibitor JAB-23E73 in KRAS-mutant pancreatic cancer and a Phase IIa study for rheumatoid arthritis drug JAB-8263, signaling pipeline progress. However, Q4 2025 revenue plunged 94.72% YoY to HKD 4.37 million, net loss widened to HKD 48.37 million, and EPS was -HKD 0.0624. The stock remains 60.38% below its 52-week high of HKD 11.8, trading below both the 20-day MA of HKD 4.882 and 60-day MA of HKD 4.831, with a YTD decline of 27.18%.

Jacobio Pharmaceuticals staged a recovery after a morning dip, closing at HKD 4.52, down 4.2% from previous close, still 61.7% below its 52-week high of HKD 11.8 and trading below both the 20-day (HKD 4.94) and 60-day (HKD 4.91) moving averages. The stock bottomed at HKD 4.325 intraday before rebounding, with a session range of over 8%. Recent share buybacks at HKD 4.64-5.08 have done little to offset fundamental headwinds: Q4 2025 revenue slumped 94.7% YoY to HKD 4.37 million, with net loss widening 781% to HKD 48.4 million, and net margin deepening to -1106.6%. However, pipeline progress continues, with the KRAS inhibitor JAB-23E73 entering a Phase Ib/III pancreatic cancer trial and JAB-8263 dosing first patient in a Phase IIa rheumatoid arthritis study, offering a counterbalance to near-term financial strain.

Jacobio Pharmaceuticals closed at HKD 4.76, down 5.18% on enlarged volume, driven by deteriorating earnings with Q4 2025 revenue plummeting 94.72% YoY to HKD 4.37M and net loss widening to HKD 48.37M (EPS -0.0624, YoY -779.73%). The stock staged a morning session spike to HKD 5.05 before reversing sharply to an intraday low of HKD 4.77 in the afternoon. Current price remains below both MA20 (HKD 5.02) and MA60 (HKD 5.071), with a 59.66% decline from the 52-week high of HKD 11.8 and a 25.86% YTD slide. However, progress in clinical programs—including first patient dosing in JAB-8263's Phase IIa rheumatoid arthritis trial and JAB-23E73's Phase Ib/III pancreatic cancer study—provided some counterbalance.